Cargando…
Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function
High-dose methotrexate (MTX; ≥1 g/m(2)) is a renally eliminated and nephrotoxic first-line therapy for central nervous system (CNS) lymphoma. Creatinine-based estimation of renal function is the recommended approach to dosing MTX in these cases, but nonrenal determinants of creatinine production and...
Autores principales: | Barreto, Jason N., McClanahan, Allison L., Rule, Andrew D., Thompson, Carrie A., Frazee, Erin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892267/ https://www.ncbi.nlm.nih.gov/pubmed/29780646 http://dx.doi.org/10.1155/2018/7169897 |
Ejemplares similares
-
A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate
por: Barreto, Jason N., et al.
Publicado: (2022) -
Cystatin C: A Primer for Pharmacists
por: Teaford, Hilary R., et al.
Publicado: (2020) -
Propsective evaluation of high‐dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function
por: Barreto, Jason N., et al.
Publicado: (2021) -
Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study
por: Frazee, Erin N, et al.
Publicado: (2014) -
Tissue Inhibitor Metalloproteinase-2 and Insulin-Like Growth Factor Binding Protein-7 Kinetics Following Exposure to High-Dose Methotrexate
por: Barreto, Jason N., et al.
Publicado: (2023)